297 related articles for article (PubMed ID: 16437629)
1. Lymphomatous involvement of gastrointestinal tract: evaluation by positron emission tomography with (18)F-fluorodeoxyglucose.
Phongkitkarun S; Varavithya V; Kazama T; Faria SC; Mar MV; Podoloff DA; Macapinlac HA
World J Gastroenterol; 2005 Dec; 11(46):7284-9. PubMed ID: 16437629
[TBL] [Abstract][Full Text] [Related]
2. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
3. Standardised uptake value of 18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma.
Papajík T; Mysliveček M; Sedová Z; Buriánková E; Procházka V; Koranda P; Raida L; Kubová Z; Palová M; Kučerová L; Flodr P; Jarkovský J; Dušek L; Indrák K
Eur J Haematol; 2011 Jan; 86(1):32-7. PubMed ID: 20874822
[TBL] [Abstract][Full Text] [Related]
4. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
5. Dual-time-point F-18 FDG PET/CT for evaluation in patients with malignant lymphoma.
Shinya T; Fujii S; Asakura S; Taniguchi T; Yoshio K; Alafate A; Sato S; Yoshino T; Kanazawa S
Ann Nucl Med; 2012 Oct; 26(8):616-21. PubMed ID: 22692457
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.
Iwamuro M; Okada H; Takata K; Shinagawa K; Fujiki S; Shiode J; Imagawa A; Araki M; Morito T; Nishimura M; Mizuno M; Inaba T; Suzuki S; Kawai Y; Yoshino T; Kawahara Y; Takaki A; Yamamoto K
World J Gastroenterol; 2012 Nov; 18(44):6427-36; discussion p.6434. PubMed ID: 23197888
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
9. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
10. Standardized uptake value based evaluation of lymphoma by FDG and FLT PET/CT.
Wang R; Zhu H; Chen Y; Li C; Li F; Shen Z; Tian J; Yu L; Xu B
Hematol Oncol; 2014 Sep; 32(3):126-32. PubMed ID: 23996464
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic role of 18F-FDG PET in gastric MALT lymphoma.
Ambrosini V; Rubello D; Castellucci P; Nanni C; Farsad M; Zinzani P; Alavi A; Tehranipour N; Al-Nahhas A; Fanti S
Nucl Med Rev Cent East Eur; 2006; 9(1):37-40. PubMed ID: 16791802
[TBL] [Abstract][Full Text] [Related]
12. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
13. PET/CT: Clinical role in lymphomas.
Papathanasiou N
Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
[No Abstract] [Full Text] [Related]
14. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
15. [18F] FDG PET in gastric non-Hodgkin's lymphoma.
Rodriguez M; Ahlström H; Sundín A; Rehn S; Sundström C; Hagberg H; Glimelius B
Acta Oncol; 1997; 36(6):577-84. PubMed ID: 9408147
[TBL] [Abstract][Full Text] [Related]
16. Value of
Alobthani G; Romanov V; Isohashi K; Matsunaga K; Watabe T; Kato H; Tatsumi M; Shimosegawa E; Hatazawa J
Hell J Nucl Med; 2018; 21(1):7-14. PubMed ID: 29550841
[TBL] [Abstract][Full Text] [Related]
17. Change of maximum standardized uptake value slope in dynamic triphasic [18F]-fluorodeoxyglucose positron emission tomography/computed tomography distinguishes malignancy from postradiation inflammation in head-and-neck squamous cell carcinoma: a prospective trial.
Anderson CM; Chang T; Graham MM; Marquardt MD; Button A; Smith BJ; Menda Y; Sun W; Pagedar NA; Buatti JM
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):472-9. PubMed ID: 25680593
[TBL] [Abstract][Full Text] [Related]
18. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose.
Römer W; Hanauske AR; Ziegler S; Thödtmann R; Weber W; Fuchs C; Enne W; Herz M; Nerl C; Garbrecht M; Schwaiger M
Blood; 1998 Jun; 91(12):4464-71. PubMed ID: 9616140
[TBL] [Abstract][Full Text] [Related]
19. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
Moog F; Bangerter M; Kotzerke J; Guhlmann A; Frickhofen N; Reske SN
J Clin Oncol; 1998 Feb; 16(2):603-9. PubMed ID: 9469348
[TBL] [Abstract][Full Text] [Related]
20. The utility of 18-F-fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non-Hodgkin lymphoma.
Muslimani AA; Farag HL; Francis S; Spiro TP; Chaudhry AA; Chan VC; Taylor HC; Daw HA
Am J Clin Oncol; 2008 Oct; 31(5):409-12. PubMed ID: 18838874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]